Instrument Inactif

Communiqués MRI Interventions Inc OTC Bulletin Board

Actions

Equipement et technologie médicale avancés

Communiqués

31/07	ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel	AQ
21/07	ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026	AQ
27/05	ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint	AQ
13/05	ClearPoint Neuro Reports First Quarter 2026 Results	AQ
13/05	ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint	AQ
29/04	ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026	AQ
22/04	ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint	AQ
20/04	ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint	AQ
17/03	ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results	AQ
23/02	CLS Q4 (Review): Low sales due to alignment discussions with ClearPoint Neuro	AQ
22/01	ClearPoint Neuro : Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe	PU
12/01	ClearPoint Neuro : Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue	PU
07/11	ClearPoint Neuro : Quarterly Report for Quarter Ending September 30, 2025 (Form 10-Q)	PU
05/11	ClearPoint Neuro : to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025	PU
08/10/25	ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be presented at the CNS Annual Meeting in Los Angeles	AQ
01/10/25	ClearPoint Neuro : Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System	PU
12/05/25	ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing	AQ
28/04/25	ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI	AQ
25/04/25	ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025	AQ
24/04/25	ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 – Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room	AQ
17/02/25	ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025	AQ
14/02/25	ClearPoint Neuro : to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025	PU
13/02/25	ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula	AQ
08/11/24	ClearPoint Neuro Reports Third Quarter 2024 Results	AQ
08/11/24	ClearPoint Neuro : Material Agreement Form 8 K	PU